Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity: an Italian experience.
Infantino M, Morena L, Di Pietro MA, Romanin B, Cimolato B, Rocca BAL, Tunnera S, Modi G, Tilli M, Grossi V, Lari B, Cerutti H, Tesi G, Anrò V, Cartocci A, Benucci M, Veneziani F, Casprini P, Manfredi M. Infantino M, et al. Among authors: grossi v. Clin Immunol. 2022 Sep;242:109091. doi: 10.1016/j.clim.2022.109091. Epub 2022 Aug 6. Clin Immunol. 2022. PMID: 35944880 Free PMC article.
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Cantini F, Niccoli L, Nannini C, Cassarà E, Kaloudi O, Giulio Favalli E, Becciolini A, Biggioggero M, Benucci M, Li Gobbi F, Grossi V, Infantino M, Meacci F, Manfredi M, Guiducci S, Bellando-Randone S, Matucci-Cerinic M, Foti R, Di Gangi M, Mosca M, Tani C, Palmieri F, Goletti D; Italian board for the TAilored BIOlogic therapy (ITABIO). Cantini F, et al. Among authors: grossi v. Semin Arthritis Rheum. 2016 Apr;45(5):519-32. doi: 10.1016/j.semarthrit.2015.10.001. Epub 2015 Oct 22. Semin Arthritis Rheum. 2016. PMID: 26607440 Review.
Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab.
Benucci M, Meacci F, Grossi V, Infantino M, Manfredi M, Bellio E, Bellio V, Li Gobbi F, Bazzichi L, Moscato P, Caputo D, Saviola G, Talotta R, Sarzi-Puttini P, Atzeni F. Benucci M, et al. Among authors: grossi v. Biologics. 2016 Mar 11;10:53-8. doi: 10.2147/BTT.S97234. eCollection 2016. Biologics. 2016. PMID: 27041992 Free PMC article.
Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study.
Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V, Manfredi M, Parisi S, Fusaro E, Batticciotto A, Sarzi-Puttini P, Atzeni F, Meacci F. Benucci M, et al. Among authors: grossi v. Immunol Res. 2017 Feb;65(1):419-422. doi: 10.1007/s12026-016-8843-5. Immunol Res. 2017. PMID: 27449503
197 results